Humanetics is a global industrial technology group that engineers safety, digital, and sensor solutions for critical environments, focusing on human-centric design. It is involved in the development of crash test dummies, virtual simulation software, integrated crash test systems, precision sensors, and laser-based material engineering. The company's solutions are applied across various sectors including automotive, aerospace, and biomedical.

Humanetics

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated

Akebia Therapeutics is a fully integrated biopharmaceutical company that addresses complications of kidney disease, with two FDA-approved products.

Metric
Company Name	Humanetics	Corcept Therapeutics Incorporated	Akebia Therapeutics
Symbol		CORT
MSH ID	COM:HUMANETICSGROUP	COM:CORCEPT	COM:KERYX
Market	PRIVATE	STOCKS	PRIVATE
Sector	Technology	Healthcare	Healthcare & Health Services
Industry	Industrial Technology	Biotechnology	Biotechnology
Country	US	US	US
Stage
Employee Count		352
Website	humaneticsgroup.com	corcept.com	keryx.com
LinkedIn
Founders

Metric
Market Cap		3.19B
Enterprise Value
Monthly Web Traffic		53.48K
Web Traffic Growth		3.98
Valuation
Raised Capital

Metric
Revenue		482.38M
Revenue (LTM)
Revenue (NTM)
Gross Profit		475.89M
EBITDA		109.64M
Operating Income		107.28M
Net Income		106.14M
EPS		1.02
Diluted EPS		0.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.99
Operating Profit Margin		0.23
EBITDA Margin		0.23
Net Profit Margin		0.23
Return on Equity		0.24
Return on Assets		0.18
Return on Capital Employed		0.22

COM:HUMANETICSGROUP

Humanetics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		24.15
P/B Ratio		4.78
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		9.13
EV Multiple		41.21

Metric
Days Sales Outstanding		39.44
Days Payables Outstanding		1.00K
Days Inventory Outstanding		435.27
Operating Cycle		476.98
Cash Conversion Cycle		-212.43
Asset Turnover		0.80

Metric
Operating Cash Flow		127.04M
Free Cash Flow		126.90M
Cash Flow to Debt		1.64K
Operating Cash Flow/Sales		0.26
Free Cash Flow Yield		0.07

Metric
Cash & Equivalents		135.55M
Accounts Receivable		-10.07M
Inventory		7.73M
Goodwill
Debt to Capitalization		0.01
Debt to Assets		0.00
Current Ratio		3.54
Quick Ratio		5.48

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.10
R&D to Revenue		0.37
SG&A to Revenue